Platform Trial News Today

Polaris Now Enrolling in GBM AGILE, Registrational Phase 2-3 Adaptive Platform Trial for Patients with GlioblastomaPolaris lead biologic ADI-PEG 20 to be Evaluated Across Multiple International Trial SitesLARKSPUR, Calif.--(BUSINESS WIRE)--#GBMAGILE--Global Coalition for Adaptive Research (LARKSPUR, CA) and Polaris...

FACTS 7 includes new module for Platform Trial designsAUSTIN, Texas--(BUSINESS WIRE)--Berry Consultants, LLC announced today that FACTS 7 was released to existing users and is now available to all new clients. FACTS (Fixed and Adaptive Clinical Trial Simulator) is the most powerful, flexible, and fastest simulation...

OTTAWA, July 7 (Xinhua) -- Canadian Health Minister Jean-Yves Duclos announced Thursday an investment to create a pan-Canadian platform to advance research into the effectiveness and clinical challenges of new COVID-19 treatments in non-hospitalized patients.

Biohaven and Vigeo Now Enrolling in GBM AGILE, Registrational Phase 2-3 Adaptive Platform Trial to Evaluate Interventions for Patients With GlioblastomaLARKSPUR, Calif.--(BUSINESS WIRE)--#GBMAGILE--Global Coalition for Adaptive Research (LARKSPUR, CA), Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), and V...

Restrictions may be easing, but COVID-19 is still well and truly with us as much of Australia shivers through winter – our first with both COVID-19 and

Ivermectin neither reduced hospital admissions for worsening COVID-19 nor shortened the time that infected patients spent in the emergency room, according to data from a large randomized controlled trial.

A new Aussie research program kicking off this week will investigate the most effective, long-term strategies for booster vaccinations.

A team of Australia’s top infectious disease experts will lead a clinical trial to determine whether combining different Covid-19 vaccines in the nation’s booster immunisation will increase effectiveness. The three-year project has been funded by a m

A team of Australia’s top infectious disease experts will lead a clinical trial to determine whether combining different Covid-19 vaccines in the

Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments - NURTEC® ODT (rimegepant) net product revenues for the fourth quarter of 2020 were $35.1 million, representing a 98% increase compared to the third quarter of 2020, and $63.6 million for calendar year 2020 following U.S. commercial launch in March of 2020 - Exceeded market expectations with robust growth of NURTEC ODT totaling over 337,000 prescriptions in 2020 and over 24,000 unique prescrib...